These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22606272)

  • 21. Estrogen receptor α (ERα) status evaluation using RNAscope in situ hybridization: a reliable and complementary method for IHC in breast cancer tissues.
    Yu X; Guo S; Song W; Xiang T; Yang C; Tao K; Zhou L; Cao Y; Liu S
    Hum Pathol; 2017 Mar; 61():121-129. PubMed ID: 27993577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
    Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
    Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
    Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
    BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.
    Zheng Y; Zhang J; Xu ZZ; Sheng JM; Zhang XC; Wang HH; Teng XD; Liu XJ; Cao J; Teng LS
    J Zhejiang Univ Sci B; 2010 Feb; 11(2):144-50. PubMed ID: 20104649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
    Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
    BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
    Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
    Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
    Darb-Esfahani S; Wirtz RM; Sinn BV; Budczies J; Noske A; Weichert W; Faggad A; Scharff S; Sehouli J; Oskay-Ozcelik G; Zamagni C; De Iaco P; Martoni A; Dietel M; Denkert C
    Endocr Relat Cancer; 2009 Dec; 16(4):1229-39. PubMed ID: 19675076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
    J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.
    Dalm SU; Sieuwerts AM; Look MP; Melis M; van Deurzen CH; Foekens JA; de Jong M; Martens JW
    J Nucl Med; 2015 Oct; 56(10):1487-93. PubMed ID: 26251419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
    Denkert C; Loibl S; Kronenwett R; Budczies J; von Törne C; Nekljudova V; Darb-Esfahani S; Solbach C; Sinn BV; Petry C; Müller BM; Hilfrich J; Altmann G; Staebler A; Roth C; Ataseven B; Kirchner T; Dietel M; Untch M; von Minckwitz G
    Ann Oncol; 2013 Mar; 24(3):632-9. PubMed ID: 23131391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
    Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
    Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.
    Lukina SS; Burdennyy AM; Zavarykina TM; Riabchikov DA; Kazubskaya TP; Kruglova MP; Loginov VI
    Bull Exp Biol Med; 2021 Jan; 170(3):350-355. PubMed ID: 33452979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
    Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
    PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.
    Babyshkina N; Vtorushin S; Dronova T; Patalyak S; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
    Clin Exp Med; 2019 Nov; 19(4):547-556. PubMed ID: 31562548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
    Du X; Li XQ; Li L; Xu YY; Feng YM
    Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.